CLINICAL TRIALS ARTICLES
-
Picasso, Pick-Up Lines, & Personalized Medicine: mRNA's Path Forward
Overall, my presentation on what the mRNA industry can learn from the artist Picasso singled out a few specific areas from which I felt our industry could garner greater inspiration and operational prowess. But given how “collaborative” many of these sources of inspiration are, I’ve introduced each of my takeaways with a surprisingly relevant (albeit bad) art-themed pick-up line. After all, if there’s one sector that knows it takes more than one to “tango,” it’s the mRNA industry.
-
Pictures At An [mRNA]Exhibition: What We Can Learn From Picasso (Pt. 1)
In my presentation, I argued that there are three lessons we can learn from Picasso that will also help our own industry mature. In the upcoming weeks, I plan to unpack these lessons, highlighting specific instances in which I see our industry taking these lessons to heart and making progress — starting here with lesson 1: Being Innovative Comes After We Master The Basics
-
"Raiders Of The Lost Codon:" Alltrna On Evolving "Ancient" tRNA Into Therapeutics
Here, in part one of this two-part article, we identify how tRNA stands apart from other RNA modalities and gene therapies, as well as how this molecule’s unique “skill set” is guiding the company’s future clinical strategy.
-
Learning From Oligos: Delivery & Clinical Strategies For mRNA Therapeutics
Those of us who attended the Alliance for mRNA Medicines’ inaugural Ascent conference last fall had the opportunity to hear from Zdravka Medarova of TransCode Therapeutics on her experiences working in the oligo sector. Here, I summarize some of her learnings and/or suggestions for the encoding RNA field as we set out to develop mRNA therapeutics for oncology.
-
Cultivating A Thriving mRNA Ecosystem: Key Initiatives & Future Directions
Overall, I felt that the following initiatives/talking points were demonstrative of the types of creativity and symbiosis that we will need much more of in the near and long-term to foster a healthy and fruitful RNA ecosystem.
-
From Promise To Precision: Defining The Therapeutic Niche for mRNA
CureVac CEO Alexander Zehnder shares his thoughts/visions on how mRNA neoantigen vaccines could become even more revolutionary for patient populations in the future. Though it may be early days, this conversation is a great case study for how RNA companies are striving to keep both scientific and commercial market opportunities top of mind from the earliest days of development.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Many clinical trial oversight problems can be avoided or mitigated by sponsor understanding root causes and being a proactive collaborator with its partners.
-
Enabling sites to focus solely on critical data facilitates faster data entry, reduces queries, and fosters better relationships between sponsors, CROs, and sites.
-
Explore the leading biotech hubs in 2025, what makes them unique, and how companies can leverage these ecosystems to accelerate innovation and growth.
-
This comprehensive overview of current and emerging obesity treatments provides insight into the growing global health crisis that is rising in prevalence across all demographics and income levels.
-
This report provides a comprehensive overview of Idiopathic Pulmonary Fibrosis (IPF), a progressive and fatal interstitial lung disease.
-
Explore the growing number of clinical trials and innovative approaches for Idiopathic Pulmonary Fibrosis (IPF) treatments.
-
The global infectious disease clinical trial landscape has rapidly expanded between 2020 and 2024, driven by the urgency of emerging threats, technological innovation, and evolving regulatory frameworks.